Local adipose tissue renin-angiotensin system

Bays H, Rodbard HW, Schorr AB, Gonzalez-Campoy JM: Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med 2007, 9:259–271. Cassis LA, Saye J, Peach MJ: Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988, 11:591–596. Campbell DJ, Habener JF: Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology 1987, 121:1616–1626. Cassis LA, Lynch KR, Peach MJ: Localization of angiotensinogen messenger RNA in rat aorta. Circ Res 1988, 62:1259–1262. Cassis LA: Fat cell metabolism: insulin, fatty acids, and renin. Curr Hypertens Rep 2000, 2:132–138. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA: Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 2007, 292:E1280–E1287. Kim S, Soltani-Bejnood M, Quignard-Boulange A, et al.: The adipose renin-angiotensin system modulates systemic markers of insulin sensitivity and activates the intrarenal renin-angiotensin system. J Biomed Biotechnol 2006, 2006:27012. Goossens GH, Jocken JW, Blaak EE, et al.: Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: effect of beta-adrenergic stimulation. Hypertension 2007, 49:542–547. Goossens GH, McQuaid SE, Dennis AL, et al.: Angiotensin II: a major regulator of subcutaneous adipose tissue blood flow in humans. J Physiol 2006, 571:451–460. Li Y, Jain S, Patil S, Kumar A: A haplotype of angiotensinogen gene that is associated with essential hypertension increases its promoter activity in adipocytes. Vascul Pharmacol 2006, 44:29–33. Jain S, Tang X, Narayanan CS, et al.: Angiotensinogen gene polymorphism at-217 affects basal promoter activity and is associated with hypertension in African-Americans. J Biol Chem 2002, 277:36889–36896. Dickson ME, Zimmerman MB, Rahmouni K, Sigmund CD: The-20 and-217 promoter variants dominate differential angiotensinogen haplotype regulation in angiotensinogen-expressing cells. Hypertension 2007, 49:631–639. Kotani K, Sakane N, Saiga K, et al.: The uncoupling protein-1 gene-3826A/G polymorphism and hypertension in Japanese subjects. Clin Chem Lab Med 2007, 45:1186–1189. Achard V, Boullu-Ciocca S, Desbriere R, et al.: Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol, 2007, 292:R274–R282. Bujak-Gizycka B, Madej J, Wolkow PP, et al.: Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). J Physiol Pharmacol 2007, 58:529–540. Cassis L, Gupte M, Boustany C, et al.: Novel expression of ACE2 in adipose tissue and regulation by PPARγ ligands and by high fat diets [abstract CHBRPP142]. Paper presented at the Council for High Blood Pressure Research Conference. San Antonio, TX; October 4–7, 2006. Ailhaud G: Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. Ann N Y Acad Sci 1999, 892:127–133. Brucher R, Cifuentes M, Acuna MJ, et al.: Larger anti-adipogenic effect of angiotensin II on omental preadipose cells of obese humans. Obesity (Silver Spring) 2007, 15:1643–1646. Skurk T, van Harmelen V, Hauner H: Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004, 24:1199–1203. Matsushita K, Wu Y, Okamoto Y, et al.: Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006, 48:1095–1102. Sarzani R, Marcucci P, Salvi F, et al.: Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond) 2007, Epub ahead of print. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808. Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830. Daugherty A, Manning MW, Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000, 105:1605–1612. Harrison D, Griendling KK, Landmesser U, et al.: Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91:7A–11A. Tsuchiya K, Yoshimoto T, Hirono Y, et al.: Angiotensin II induces monocyte chemoattractant protein-1 expression via nuclear factor-kappa B-dependent pathway in rat preadipocytes. Am J Physiol Endocrinol Metab 2006, 291:E771–E778. Kurata A, Nishizawa H, Kihara S, et al.: Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70:1717–1724. Yvan-Charvet L, Bobard A, Bossard P, et al.: In vivo evidence for a role of adipose tissue SR-BI in the nutritional and hormonal regulation of adiposity and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 2007, 27:1340–1345. Iwai M, Chen R, Imura Y, Horiuchi M: TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007, 20:579–586. Zorad S, Dou JT, Benicky J, et al.: Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 2006, 552:112–122. Vague J: The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956, 4:20–34. Giacchetti G, Faloia E, Mariniello B, et al.: Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002, 15:381–388. Shimabukuro M, Tanaka H, Shimabukuro T: Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 2007, 25:841–848. Engeli S, Bohnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356–362. Garg A, Fleckenstein JL, Peshock RM, Grundy SM: Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 1992, 75:358–361. Abate N, Garg A: Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog Lipid Res 1995, 34:53–70. Soltis EE, Cassis LA: Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens 1991, 13:277–296. Takemori K, Gao YJ, Ding L, et al.: Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 2007, 49:365–372. Segura J, Ruilope LM: Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr 2007, 10:1151–1155. Kintscher U, Bramlage P, Paar WD, et al.: Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the treat to target post-authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol 2007, 6:12. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation 2007, 115:1991–1998. Schindler C, Bramlage P, Thoenes M, et al.: Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs. Clin Drug Investig 2007, 27:707–717. Bestermann W, Houston MC, Basile J, et al.: Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005, 329:292–305.